Emergent BioSolutions (EBS) Inventory (2010 - 2026)

Emergent BioSolutions' Inventory history runs 17 years deep, the most recent figure standing at $327.6 million for Q1 2026.

• On a quarterly basis, Inventory rose 4.33% year-over-year to $327.6 million in Q1 2026; TTM through Mar 2026 was $327.6 million, a 4.33% increase from a year earlier, with the FY2025 full-year figure at $343.4 million, up 10.17% from the prior year.
• Inventory declined to $327.6 million in Q1 2026 per EBS's latest filing, from $343.4 million in the prior quarter.
• Across five years, Inventory topped out at $528.2 million in Q3 2022 and bottomed at $311.7 million in Q4 2024.
• The 5-year median for Inventory is $343.4 million (2025), against an average of $357.4 million.
• Across the five-year window, Inventory soared 44.87% in 2022 and slumped 32.96% in 2023, its largest moves.
• Year by year, Inventory stood at $350.7 million in 2022, then dropped by 6.22% to $328.9 million in 2023, then decreased by 5.23% to $311.7 million in 2024, then advanced by 10.17% to $343.4 million in 2025, then decreased by 4.6% to $327.6 million in 2026.
• Per Business Quant, the three latest EBS Inventory figures stand at $327.6 million (Q1 2026), $343.4 million (Q4 2025), and $356.3 million (Q3 2025).